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Abstract 
WHO reported that viral diseases remain as an international public health concern. Quite a lot of viral 
outbreaks such as the SARS coronavirus from 2002 to 2003, H1N1 influenza in 2009, and the MERS 
syndrome coronavirus in 2012, in the last two decades. The recent outburst of COVID-19 disease has to 
turn out a global public health catastrophe that has a profound consequence on every aspect of human life. 
Currently, national governments, international health agencies, UN different bodies are working 
relentlessly to find the best way to save and mitigate our world from the shattering effects of COVID-19. 
Simultaneously, all related scientists around the planet determinedly made enormous efforts to find the 
COVID-19 transmission process, clinicopathological issues, diagnostics tools, and prevention policy 
planning and pharmacological intervention approaches. There are many problems that are not resolved 
regarding COVID-19, like the virus-host relations and the development and progression of the pandemic, 
with precise reference to the times when the current pandemic will reach its ultimate level to produce 
maximum damage. At this moment in time, yet we do not possess and definite and specific treatment 
options to fight with the COVID-19 viral infectious diseases. Currently, the majority of the scientist is 
involved in finding a way through drug repurposing. Up to the present time lot of medicines were identified 
that possess definite antiviral effects against COVID-19 but need to go a long way with well-designed study 
to obtain the best possible answer. After that, to this point, supportive and preventive remain as the best 
weapon. 
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Introduction 
Microbial diseases (bacteria, viruses, parasites, and fungus) have instigated disaster throughout human 
history [1]. Emerging and re-emerging microbial diseases along with multiple drug-resistant (MDR), 
pandrug-resistant (PDR), extensively drug-resistant (XDR) are now taking place at skyrocket high-speed [2-
4]. The World Health Organization (WHO) reported that our planet has feast your eyes on the escalation of 
quite a lot of infectious disease eruptions and epidemics began by more than twenty infectious agents over the 
last ten years [5]. These epidemics were often of novel viral origin such as a novel influenza A virus (H1N1) 
and Middle East respiratory syndrome (MERS) [6-10]. 
The evolution of coronavirus-associated diseases, Severe Acute Respiratory Syndrome (SARS and 
MERS) for the last twenty years, imposed comprehensive international challenges regarding the management 
of these viral diseases and ensured a threat to public health all over the globe [11,12]. The SARS-CoV-2 is the 
causative virus agent for coronavirus disease (COVID-19), the latest version of the β-coronavirus family, 
single-stranded RNA, the enveloped virus that is 50-200 nm in diameter [13-16], after that, the WHO 
confirmed COVID-19, a public health emergency of global distress on January-30-2020 and a pandemic on 
March-11-2020 [17-19]. The mortality total and daily new death profile of selected countries are depicted in 
Figures 1 and 2. Total death till June 13-2020 due COVID-19 was 425, 931 (Figure 3). 
 
 
Source: European CDC – Situation update worldwide – Last update 13th June 2020. 
Figure 1. Illustrated total confirmed COVID-19 deaths per million people. 
 
The World Health Organization promoted these strategies to prevent COVID-19 transmission [20]: 
1) Clean your hands frequently with soap and water, or an alcohol-based hand sanitizer; 2) Conserve a safe 
space from any person who is coughing or sneezing; 3) Avoid touching your own eyes, nose or mouth; 4) Shield 
your nose and mouth with your bent elbow or tissue while you are coughing or sneezing; 5) Stay home; 6) If 
you develop a fever, cough and difficulty breathing, urgently seek medical care; 7) Comply and conform the 
directions of your local health authority; 8) Avoid unnecessary visits to clinics and hospitals facilities that will 
reduce the possibility of acquiring COVID-19 infection; additionally, permits healthcare systems to function 
more efficiently, consequently protecting you and others. 
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Source: European CDC – Situation update worldwide – Last update 14th June 2020. 
Figure 2. Illustrated daily new COVID-19 deaths. 
 
 
 
Source: European CDC – Situation update worldwide – Last update 13th June 2020. 
Figure 3. Total confirmed COVID-19 deaths in world, high, upper-middle, lower-middle, low-income, 
and a few selected countries. 
 
COVID-19 and Intensive Care Unit 
Coronaviruses are an outsized family of viruses that are recognized to driving force sickness 
extending from the common cold to more ascetic illnesses such as MERS, SARS, and the current global 
pandemic of COVID-19 [21,22]. There is no explicit pharmacological intervention, curative treatment, and 
vaccine caused by the novel coronavirus [21,23]. Nevertheless, many of the pathological issues of COVID-19 
currently managed with available clinical options, and consequently, current treatment planning principally 
founded on the individual patients’ clinical context [24-26]. Additionally, COVID-19 patients frequently need 
supportive medical care, including the Intensive Care Unit with ventilator, and dialysis as these found highly 
effective in saving lives [27-29]. 
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Collaborative research of WHO and the Chinese Government reported that 6.1% of COVID-19 
patients were categorized as critically sick with respiratory failure, shock, and impaired function multiple vital 
organs or even failure [30]. Additionally, 13.8% of patients develop severe dyspnea with respiratory rate 
30/30+ per minute, oxygen saturation 93% or less, the partial pressure of arterial oxygen to fraction of 
inspired oxygen [PaO2/FiO2] ratio below 300 mm Hg, and increase in lung infiltrates over 50% within 24-48 
hours [30]. 
All severe cases of COVID-19 do not need ICU service and care. Certainly, ICU admissions are reliant 
on the harshness of disease and the ICU availability of the healthcare system [27]. One Italian study reported 
that among the 1581 COVID-19 patients with ICU related data (March/2020). This study out of 1581 patients 
920 (58%; 95% CI 56%-61%) were continued in the ICU, 256 (16%; 95% CI 14%-18%) were cured and released 
from the ICU, and 405 (26%; 95% CI 23%-28%) had passed away in the ICU. Elderly patients (n=786; age 64 
years and above) had higher rate of death than younger patients (n=795; age 63 years or below) (36% vs. 15%; 
difference, 21%; 95% CI 17%-26%; p<0.001). After that, around 26% the rate of the fatal outcome of COVID-19 
in Italy [31]. 
One Canadian study conducted between February to April/2020 among 117 diagnosed case of 
COVID-19 required ICU care and service. The age range was 60-75 years, and 67.5% and 32.5% were male 
and female, respectively. Additionally, 73.5% of patients admitted in ICU have as a minimum one comorbidity 
and 63.2% required invasive mechanical ventilation. Overall, the duration of mechanical ventilation was 13.5 
days (Interquartile Range; IQR = 8-22) and 11 days (IQR = 6-16) for patients achieved good clinical outcomes 
and released. A total of 15.4% of patients had died till May/2020, 10.3% patients’ improvement was slow and 
continued the need of the ICU care, and 13.7% were released from the ICU but endured in hospital, and 60.7% 
were cured, released from the hospital and reached home [32]. 
One the US reported that out of twenty-four definite COVID-19 patients admitted in ICU service, 
58% had diabetes mellitus. Among these patients, 50% of cases passed away from day-1 to day-8. Remaining 
50% patients survived, 21% were cured, released and go home, 17% were released from the ICU care, but the 
improvement was not enough, thereby, need to stay in the hospital, and 12% patients were not improved and 
needed continuing to receive mechanical ventilation in the ICU. The study concluded that the full picture 
requiring the ICU service was a hypoxemic respiratory failure [33]. 
A prospective study was conducted in hospitals allied with Columbia University, New York, USA, 
between March/2020 to April/2020. In this time frame, 1150 cases of laboratory-confirmed COVID-19 were 
admitted, and among them, 22% were in severe condition. The median age of these COVID-19 patients was 62 
years (IQR 51-72); additionally, 67% and 33% were men and women, respectively. Moreover, 82% of admitted 
patients had at least one comorbidity, such as hypertension (63%), diabetes (36%), and obesity (46%). Among 
these admitted cases, 39% and 37% were passed away and continued hospitalization till April/2020. Invasive 
mechanical ventilation was required among 79% cases for a median of 18 days (IQR 9-28), with 31% need 
hemodialysis. Among these patients very seriously deteriorated by the median time three days (IQR 1-6). This 
study found among the elderly population (Adjusted Hazard Ratio; aHR = 1.31; 1.09-1.57) per 10-year 
increase). The statistical analysis when conducted among non-communicable-disease comorbidity revealed that 
chronic cardiac disease, chronic pulmonary disease, higher concentrations of interleukin-6, and higher 
concentrations of D-dimer were exclusively correlated with hospital-admitted patients’ mortality (aHR = 1.76; 
1.08-2.86), (aHR = 2.94; 1.48-5.84), (aHR = 1.11; 95%CI 1.02-1.20; per decile increase), (aHR = 1.10; 1.01-1.19; 
per decile increase), respectively [34]. 
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The Scottish Government has proclaimed till June/2020 that a total of 220,198 Scottish population 
have been examined for COVID-19. Among these, 202,121 and 18,077 were confirmed negative and positive, 
respectively [35]. In Scotland, those patients admitted ICUs 38% of COVID-19 do not recover and expire 
[36]. Among Scottish patients required ICUs, they need about 80%, almost 80%, and nearly 30% required 
advanced respiratory support, cardiovascular support, and dialysis, respectively [36]. Médecins Sans 
Frontières [(MSF) Doctors Without Borders] reported in Brazil, between 15,000-30,000 are infected with 
COVID-19 every day, over 43,000 passed away and closely 870,000 cases. Additionally, the mortality rate is 
highest among nursing staff in Brazil than any other country around the planet. Around one hundred nurses 
are dying every month because of the global pandemic of COVID-19 [37]. Nevertheless, another study 
reported in June/2020 that in Brazil, total COVID-19 cases (Figure 4), mortality (Figure 5), and recovered was 
983,359, 47,869, and 520,360, respectively [38]. 
 
 
Source: European CDC – Situation update worldwide – Last update 25th June 2020. 
Figure 4. Illustrated total confirmed COVID-19 cases. 
 
 
Source: European CDC – Situation update worldwide – Last update 25th June 2020. 
Figure 5. Total confirmed COVID-19 deaths in Brazil. 
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Currently Utilized Medication for COVID-19: Clinically Approved for Other Indication 
Currently, there are no specific and approved medicines for the treatment of COVID-19 infections. 
Though there are a lot of efforts are ongoing. Subsequently, a systematic review was conducted based on 
currently published research regarding chloroquine (CQ) and hydroxychloroquine (HCQ). This study 
supported the utilization of both CQ and HCQ – as because two medicines are in clinical use for 86 years for 
other diseases like malaria, rheumatoid arthritis, and systemic lupus erythematosus. This review revealed the 
risk regarding these age-old medicines at minimum risk. As there has been enough time has passed to study 
post-market surveillance. Moreover, both medications are cost-effective; additionally, HCQ is approved in 
many countries, since 2014 as a third- or fourth-line drug, diabetes mellitus [39]. 
Similarly, multiple studies reported that efficacy and safety issues are worth utilizing CQ and HCQ in 
the absence of specific drugs to combat the global pandemic [40-42]. On the contrary, June 15, 2020, the US 
Food and Drug Administration (FDA) rescinded the emergency use authorization (EUA) that permitted CQ 
and HCQ to use for the treatment of COVID-19 hospitalized patients. The FDA assessed that the allowable 
principles for allotting a EUA are no longer come across. After that, the FDA decided CQ and HCQ are not 
effective and safe in treating COVID-19 under the EUA provision. The decision to canceled EUA was based on 
evolving scientific data and constant analysis of the clinical outcome [43]. 
A recent systematic review and meta-analysis reported that studies, although HCQ + azithromycin 
(Azi) appears safe and effective. Nevertheless, more multi research studies with large data sizes are obligatory 
for an ultimate inference. Additionally, this review reported that HCQ has better shreds of evidence and 
promising efficacy and safety profile to avert radiological progression (deterioration) of COVID-19 cases when 
compared with control or conventional treatment group [44]. The French group of researchers reported that 
HCQ + Azi combination when applied to COVID-19 patients, it was successfully eradicated 100% virological 
load when compared with the HCQ alone (57.1%) and the control (12.5%) group [45]. The same research 
group in their second study with a higher number sample size revealed that HCQ + Azi combination reduces 
83% and 93% of the virological load of COVID-19 cases on day-seven and day-eight, respectively. It was 
reported that 81.25% were cured and released from the hospital [46]. The identical research cluster in their 
third study with an additional number sample than the second study reported that HCQ + Azi combination 
diminishes 91.7% of the virological load among COVID-19 patients by day-ten and the unfortunate clinical 
consequence was observed in only 4.3% patients, and 0.47% patients passed away [47]. 
Another French group of researchers 48 working separately revealed quite the reverse findings and 
were unsuccessful in imitating the earlier results [45-47]. The case selection of this study was much different 
[48]. These COVID-19 patients belong to the severe category with multiple substantial comorbidities like 
carcinoma, HIV, and over-weight [48]. It was reported that HCQ + Azi combination causes mild adverse drug 
reactions (ADRs) that include nausea, vomiting, diarrhea, and blurring of vision [46]. Another study reported 
that only one of their study participants developed electrocardiographic changes of QT prolongation [48]. 
Another study showed that 11% of research participants of COVID-19 cases with these combination 
antimicrobials developed substantial QTc prolongation. Additionally, those cases develop of acute renal failure 
was an imperative forecaster of extreme QTc prolongation [49].  
A study was conducted in New York among 1438 COVID-19 hospitalized male patients with a median 
age of 63 years receiving HCQ, Azi, or both. This study revealed that in general COVID-19 hospital admitted 
patients' death rate was 20.3% (95% CI; 18.2%-22.4%). The possibility of passing-away for patients receiving 
HCQ + Azi was 189/735 (25.7%; 95% CI 22.3%-28.9%), HCQ alone, 54/271 (19.9%; 95% CI 15.2%-24.7%), Azi 
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alone, 21/211 (10.0%; 95% CI 5.9%-14.0%), and not-at-al medication, 28/221 (12.7%; 95% CI 8.3%-17.1%). In 
adjusted Cox proportional hazards models when compared with patients receiving not either medicine, there 
were no statistically significant differences observed regarding death rate for patients receiving HCQ + Azi 
(HR = 1.35; 95% CI 0.76-2.40), HCQ singly (HR = 1.08; 95% CI 0.63-1.85), or Azi exclusively (HR = 0.56; 
95% CI 0.26-1.21). In logistic models analysis found patients receiving none of two cardiac arrests was 
significantly more expected among patients receiving HCQ + Azi (Adjusted OR = 2.13; 95% CI 1.12-4.05), but 
not hydroxychloroquine singly (Adjusted OR = 1.91; 95% CI 0.96-3.81) or Azi solely (Adjusted OR = 0.64; 
95% CI 0.27-1.56). In adjusted logistic regression models, there were no statistically significant changes 
observed in the comparative possibility of atypical electrocardiogram results. Consequently, this study finally 
concluded that pharmacological intervention with HCQ, Azi, alone, or HCQ + Azi (combination) was not 
correlated with statistically significantly in lowering mortality, among COVID-19 hospitalized patients [50]. 
As there are no definite or specific treatment options, by this means, the global pandemic COVID-19 initiated 
available medicine repurposing is viewed as the instantaneous choice [51]. 
 
Computational Drug Repurposing and Repositioning 
Computational drug repurposing (as well recognized as drug repositioning) intentions at identifying 
new clinical indication for by now available and clinically utilized for indication, exclusively when the thorough 
3D structures of significant viral proteins are invented within five days [52-54]. Drug repurposing has 
developed as a dynamic division of medicine invention for novel clinical indication [52]. 
Accordingly, there has been a blast in drug repurposing experiments to invent innovative medicines as 
aspirants and research studies regarding circumstantial findings. One second-generation cephalosporin - 
Cefuroxime has been spotted with quite a lot of anecdotal benefits in the treatment of COVID-19 [51]. In that 
way, one scoping review reported that cefuroxime reveals promising efficacy in opposing three significant 
COVID-19 proteins necessary for replication in drug repurposing experimentations. In this manner, 
cefuroxime possibly possesses auspicious multi-target pharmacodynamics that can help us to combat the 
current pandemic [51]. Additionally, cefuroxime was approved by the US FDA in 1998. Subsequently, it has a 
long history for clinical use and post-market-surveillance that raises it as a reliable alternative for additional 
research studies in the global battle against COVID-19 – the current highest threat of human existence 
[51,55]. 
Computational drug repurposing studies have already identified several clinically available medicines 
that possess potential pharmacodynamics to inhibit COVID-19 principal protease responsible for viral 
replication and transcription.  Those antimicrobials include - carfilzomib, eravacycline, valrubicin, lopinavir, 
lopinavir-ritonavir, tipranavir, raltegravir taxifolin rhamnetin, elbasvir, ivermectin, and many more upcoming 
[54,56-60]. 
Ivermectin was FDA-approved for parasitic infections in 1996 for the treatment of strongyloidiasis 
and onchocerciasis [61]. However, ivermectin is an antiparasitic medicine but possesses a broad-spectrum 
antiviral activity in experimental studies outside of a living organism, including the COVID-19 virus [59]. It 
has around 5000 times the potential to reduce viral load at 48 hours in cell-line culture [59]. Another study 
reported similarly that ivermectin possesses broad-spectrum antiviral efficacy to inhibit viral replication and 
transcription of numerous animal and human viruses, which include both RNA and DNA viruses. The broad-
spectrum antiviral property of ivermectin depends on through the inhibition of importin α/β-mediated nuclear 
transport of viral proteins. The identical pharmacodynamics of ivermectin was observed with COVID-19. This 
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study finally concluded that the beneficial clinical potential and ADRs of ivermectin yet not adequately 
assessed in prescribing COVID-19 patients [60]. 
 
Convalescent Plasma Therapy 
Passive immunization (PI) and antibody therapy had been over a hundred years back. After that, 
convalescent plasma therapy is a long-standing therapeutic resource with new evidence for the discouragement 
and treatment of hypoimmunoglobulinemias, carcinoma, and human infectious diseases such as measles, 
hepatitis A, hepatitis B, tetanus, varicella, rabies, and vaccinia [62-64]. 
The availability and easy accessibility of antimicrobials had put down, and PI therapy issues went 
exile and considered as out-of-date treatment options for especially infectious diseases [63]. The advent of 
multi-drug resistant (MDR) pathogenic microbial contagious diseases, and laterally with the initiation of novel 
monoclonal antibody synthesis methods has to reawaken, and PI technique has been returned in clinical 
medicine PI [63]. 
Convalescent plasma had been prescribed as the last remedy among gravely sick SARS patients who 
were continued to worsen despite having methylprednisolone. Additionally, multiple research reported that 
convalescent plasma reduces hospital stay and death rates than those who did not have [65-68]. WHO in 2014 
recommended prescribing and utilizing convalescent plasma as an empirical therapeutic option during the 
Ebola epidemic in Western Africa [69,70]. A similar treatment code of practice had been developed to use 
convalescent plasma as a last resort for therapeutic intervention among severely sick MERS patients’ 
management program in 2015 [71,72]. 
The mortality risk of COVID-19 infection, pneumonia, and acute respiratory distress syndrome 
(ARDS) among critically ill patients over 65 years old remains extremely high, around 12%. It was observed 
these patients passed away by one to two weeks after admitted in ICU [73,74]. Multiple studies have been 
reported that human convalescent plasma of COVID-19 patients appeared to be a safe and possesses high 
prospect and possibilities for beneficial effects among the current global epidemic patients and asymptomatic 
cases with exposure to COVID-19 sick individual [21,75-77]. Multiple recent research studies reported that 
convalescent plasma therapy was well tolerated among COVID-19 patients and improved the clinical 
consequences through reducing viral load and deactivating coronavirus virulence potential [78-81]. 
Nonetheless, it is judgmentally imperative to conduct well-designed controlled clinical studies to establish 
efficacy, the optimum number of convalescent plasma transfusion, and to ascertain the appropriate time of 
administration. Thereby determine the clinical benefit of convalescent plasma therapy, and it can be 
generalized to notify the rationality of convalescent plasma therapy has been developed based on scientifically 
proven evidence [75,78]. 
 
Role of Clinical Available Antiviral Medication in COVID-19 
The US FDA issued a EUA for the broad-spectrum antiviral agent remdesivir for severe laboratory 
polymerase chain reaction (PCR) positive cases or suspected COVID-19 hospital admitted to both adults and 
pediatric patients [82,83]. Remdesivir is a nucleotide analog RNA polymerase inhibitor. The clinical trial was 
conducted in the Democratic Republic of Congo regarding remdesivir efficacy on Ebola virus infections 
revealed insubstantial clinical advantageous potential [84]. 
Multiple studies showed that remdesivir exhibits potential pharmacodynamics to inhibit replication 
and transcription of other human coronaviruses such as SARS-CoV in 2003 and MERS-CoV in 2012 [85-87]. 
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Additionally, remdesivir antiviral pharmacodynamic was evidenced in animal models that have been confirmed 
for SARS-CoV and MERS-CoV [85]. It has been reported that Remdesivir is one of the top computational 
drug repurposing, and repositioning agents possess promising pharmacodynamics to combat COVID-19 
[88,89]. 
Multiple studies reported that Remdesivir is one of the top computational drug repurposing, and 
repositioning agents possess promising pharmacodynamics to combat COVID-19 [88-90]. On the contrary, 
some studies indicated that remdesivir was not correlated with statistically significant clinical benefits among 
severe COVID-19 patients [91,92]. One systematic review comprising of twenty original studies regarding 
lopinavir-ritonavir antiviral efficacy against COVID-19. Among these studies, twenty, one, and one research 
studies were conducted in China, South Korea, and Singapore, respectively. The current systematic review 
revealed that there were no sharply identified antiviral pieces of evidence found with this combination 
(lopinavir-ritonavir) in improving COVID-19 patients or not.  The present state of affairs of the global 
pandemic of COVID-19 is a severe ‘red flag” for universal health-related organizations, including WHO [93]. 
This study finally concluded that the current global pandemic – COVID-19 and yet to come epidemics, health-
related organizations including WHO should trail more pre-emptive activities and well-designed strategy for 
clinical trials to obtain high-quality clinical results that can face imminent epidemics [93]. 
 
Systemic Corticosteroids 
WHO, in general, does not recommend corticosteroids are for the treatment of COVID-19 pneumonia 
[94]. Additionally, it was reported that the use of systemic glucocorticoids in the treatment of acute 
respiratory distress syndrome (ARDS) secondary to viral pneumonia is debatable [95]. The reason for non-
recommendation glucocorticoids; as the administration of these steroids lengthen and protract viral clearance 
and increased risk of secondary infection [96]. Even though there are not much data available regarding the 
use of glucocorticoids among COVID-19 pneumonia [96], nevertheless, mostly, no single exclusive evidence 
subsists to anticipate that patients with COVID-19 infection can improve with glucocorticoids. 
Moreover, researchers have intense apprehension of worsening and further aggravation of the disease 
process [97]. Furthermore, earlier studies regarding SARS and MERS revealed that no correlation of 
glucocorticoids with deterring mortality. Nonetheless, steroids' administration correlated with deferred viral 
clearance from the pulmonary tree and blood and elevated possibilities of complications, including 
hyperglycemia, psychosis, and avascular necrosis [98,99]. Additionally, one systematic review and meta-
analysis comprising of ten research studies in 2029 among 6548 influenza caused pneumonia patients. This 
study found that glucocorticoids were correlated with an increased risk of mortality (Risk Ratio = 1.75; 95% CI 
1.30-2.36; p=0.0002), and secondary infections (Risk Ratio = 1.98; 95% CI 1.04-3.78, p=0.04) [100]. 
COVID-19 has elicited a vast number of deaths and remarkable economic destruction give rise to 
international threat not only for healthcare but also in every aspect of life. Henceforth, the current pandemic of 
COVID-19 identified the pressing necessity of therapeutic options with specific antiviral pharmacodynamic 
against SARS-CoV-2. The globe needs to wait and look forward to new scientific development to fightback 
with COVID-19. In the meantime, preventive measures are considered as the best possible way. Finally, 
COVID-19 teaches us the healthcare system almost all countries need to total overhaul based on primary 
health care policy planning to fight against any future or health crisis [101-107]. 
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Conclusion 
The COVID-19 pandemic has currently gone into a catastrophic new chapter. The earlier epidemic of 
SARS and MERS was much slower to spread around the globe than COVID-19. Increased globalization, 
international traveling, and virus adaptability in almost all countries equally often reported as the primary 
reasons for rapid spread. Another reason frequently appeared globally risk assessment regarding COVID-19 
virulence capacity the globe fails to appraise in time. To date, there is no single specific therapeutic option for 
battling against this virus. 
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